MediWound (NASDAQ:MDWD) Announces Quarterly Earnings Results

MediWound (NASDAQ:MDWD) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.42, RTT News reports. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 68.75%. During the same period in the previous year, the company earned ($0.07) EPS.

Here are the key takeaways from MediWound’s conference call:

• EscharEx remains the company’s main development priority, but the VALUE Phase III study has been pushed back by one quarter, with enrollment now expected to finish by the end of Q1 2027. Management said the delay was driven by operational issues in Europe and the burden of frequent wound assessments, not by safety or efficacy concerns.
• The company said its EscharEx collaboration network has expanded to include nearly all major advanced wound care players, now adding Medline. This broader industry involvement was presented as external validation of EscharEx and could support future commercialization and additional studies in DFU and pressure ulcers.
• NexoBrid continued to gain commercial and strategic traction, with Vericel reporting growth in ordering centers and total orders in the U.S. burn market. MediWound also highlighted a new 10-year BARDA contract worth up to $197 million, with procurement and development expected to begin in the second half of 2026.
• First-quarter 2026 revenue fell to $1.5 million from $4.0 million a year earlier, mainly because of the timing of BARDA-related revenue and shipment delays tied to regional conflict. The quarter also reflected higher R&D spending on the EscharEx VALUE study, contributing to a wider operating loss.
• Management reaffirmed full-year 2026 revenue guidance of $24 million to $26 million, expecting a second-half weighted ramp from government-related development services and procurement. The company said it is working through EMA pre-audit modifications at its expanded manufacturing facility and expects those activities to be completed in the second half of 2026.

MediWound Stock Up 1.6%

Shares of NASDAQ MDWD opened at $14.56 on Friday. MediWound has a 52-week low of $14.14 and a 52-week high of $22.50. The firm has a fifty day moving average of $16.68 and a 200-day moving average of $17.46. The stock has a market capitalization of $187.10 million, a PE ratio of -6.44 and a beta of 0.21.

MediWound News Roundup

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on MediWound and set a $36 price target, implying substantial upside from recent trading levels. Benzinga report on HC Wainwright rating
• Positive Sentiment: The company said its EscharEx Phase III VALUE trial is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027, reinforcing the long-term pipeline story. MediWound Q1 2026 financial results and corporate update
• Neutral Sentiment: MediWound reported a quarterly loss of $0.23 per share, which was better than expected, but revenue of $1.48 million fell short of estimates. The company also reaffirmed 2026 revenue guidance of $24 million to $26 million. MediWound Q1 2026 financial results and corporate update
• Neutral Sentiment: Short-interest data showed 0 shares reported, so there is no meaningful new bearish signal from that item.

Institutional Trading of MediWound

Several institutional investors have recently made changes to their positions in MDWD. Kotler Kevin purchased a new stake in shares of MediWound during the 4th quarter valued at $6,225,000. Millennium Management LLC grew its stake in shares of MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 136,884 shares during the period. Sphera Funds Management LTD. grew its stake in shares of MediWound by 24.3% during the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after buying an additional 45,077 shares during the period. Summit Financial LLC grew its stake in shares of MediWound by 200.1% during the 4th quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company’s stock valued at $886,000 after buying an additional 32,006 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of MediWound by 22.8% during the 4th quarter. Geode Capital Management LLC now owns 120,101 shares of the biopharmaceutical company’s stock valued at $2,217,000 after buying an additional 22,268 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on MDWD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of MediWound in a research report on Thursday. Finally, Oppenheimer reissued an “outperform” rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $34.00.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.